key: cord-0711121-dzcavf5a
authors: Higgins, Stephen T.; Slade, Eric P.; Shepard, Donald S.
title: Decreasing Smoking During Pregnancy: Potential Economic Benefit of Reducing Sudden Unexpected Infant Death
date: 2020-08-17
journal: Prev Med
DOI: 10.1016/j.ypmed.2020.106238
sha: aa7d4185365b0acb0bc3db657c9326594cf6190f
doc_id: 711121
cord_uid: dzcavf5a

Abstract Sudden Unexpected Infant Death (SUID) remains the leading cause of death among U.S. infants age 1-12 months. Extensive epidemiological evidence documents maternal prenatal cigarette smoking as a major risk factor for SUID, but leaves unclear whether quitting reduces risk. This Commentary draws attention to a report by Anderson et al. (Pediatrics. 2019, 143[4]) that represents a breakthrough on this question and uses their data on SUID risk reduction to delineate potential economic benefits. Using a five-year (2007-11) U.S. CDC Birth Cohort Linked Birth/Infant Death dataset, Anderson et al. demonstrated that compared to those who continued smoking, women who quit or reduced smoking by third trimester decreased the adjusted odds of SUID risk by 23% (95% CI, 13%-33%) and 12% (95% CI, 2%-21%), respectively. We applied these reductions to the U.S. Department of Health and Human Services’ recommended value of a statistical life in 2020 ($10.1 million). Compared to continued smoking during pregnancy, the economic benefits per woman of quitting or reducing smoking are $4700 (95% CI $2700-$6800) and $2500 (95% CI, $400-$4300), respectively. While the U.S. obtained aggregate annual economic benefits of $0.58 (95% CI, 0.35-0.82) billion from pregnant women who quit or reduced smoking, it missed an additional $1.16 (95%CI 0.71-1.60) billion from the women who continued smoking. Delineating the health and economic impacts of decreasing smoking during pregnancy using large epidemiological studies like Anderson et al. is critically important for conducting meaningful economic analyses of the benefits-costs of developing more effective interventions for decreasing smoking during pregnancy.

gestational length, delivery method, infant sex and birth weight). They examined 20,685,463 births and 19,127 cases of SUID. Confirming prior evidence, maternal smoking during pregnancy was associated with twice the adjusted odds ratio (aOR) of SUID compared to not smoking (aOR = 2.44; 95% CI, 2.31-2.57). Adding important new information, Anderson et al. demonstrated that compared to those who continued smoking, women who (1) quit or (2) reduced smoking by the third trimester decreased the adjusted odds (aOR) of SUID risk by 23% (95% CI 13%-33%) and 12% (95% CI 2%-21%), respectively. They also detailed how smoking even as little as 1 cigarette per day through pregnancy increased the risk of SUID by 98% (aOR = 1.98; 95 CI, 1.73-2.28), with odds increasing linearly thereafter by 0.07 for every additional cigarette smoked per day before flattening out at 20+. Anderson et al. (2019) concluded appropriately, in our opinion, that these relationships met criteria for inferring causality in that there was (1) a strong empirical association; (2) a dose-response relationship;

(3) a logical temporal order to the relationships (i.e., smoking preceded SUID); (4) findings consistent with an extant scientific literature (smoking is a well-established risk factor for SUID-see USDHHS, 2018, Chapter 4); (5) biological plausibility (plausible accounts of the pathophysiology underpinning smoking and SUID risk have been detailed--see Horne et al., 2002; Mitchell et al., 2006; Mitchell, 2009; Parsiow et al., 2004) ; and (6) decreases in risk when smoking is reduced or discontinued (i.e., if smoking is the cause, then decreasing or eliminating it should reduce risk).

Like all studies, the Anderson et al. (2019) study has limitations common in this area of investigation. The most substantive, in our opinion, is the exclusive reliance on maternal self-reported smoking status, which is common in epidemiological studies but nevertheless problematic as pregnant women often fail to disclose ongoing smoking. Nondisclosure of smoking during pregnancy is well established (Dietz et al., 2011; England et al., 2007; Tong et al., 2015) , with rates among U.S. pregnant women when queried on quitting during the current pregnancy estimated at ~30% (England et al., 2007) . This pattern of nondisclosure leads to categorizing women who are continuing to smoke as J o u r n a l P r e -p r o o f Journal Pre-proof quitters, thereby diminishing the estimated benefit of quitting on SUID risk. Nondisclosure is more common among lighter than heavier smokers, but when dealing with SUID where risk increases substantially even among light smokers, the impact on risk estimation is nevertheless likely to be diminished.

An additional limitation was not controlling for maternal alcohol or illicit drug use. We are unaware of quantitative parsing of the effects of other substance use during pregnancy on SUID risk comparable to what we have described above for nondisclosure of smoking. Adjustment for alcohol use during pregnancy did not significantly influence estimated smoking risk for stillbirth or infant mortality in the one prior study we know of on this topic (Wisborg et al. 2001) , although in a later study both were demonstrated to be independent risk factors for infant death, with the greatest level of risk compared to nonusers being seen among women who continued using both substances (Elliott et al., 2020) . Combined use of cigarette smoking and illicit drug use is well documented (e.g., Oga et al., 2018) , but less is known about their independent contributions to SUID. The likely impact of these two limitations on estimated smoking-attributable risk would likely be in opposite directions. While they merit mention they certainly do not undermine the importance of the Anderson et al. findings on the benefits of decreasing smoking during pregnancy on SUID risk.

Epidemiological studies of this type provide critically important information for examining the comparative benefits and costs of interventions to reduce smoking during pregnancy. The reason is that while catastrophic in nature, many serious adverse health effects of smoking are relatively rare (e.g., SUID) or sufficiently delayed in time (e.g., smoking attributable lung and other cancers) to be impractical to include in smoking-cessation intervention studies be they randomized controlled trials or examining the economic benefits of decreasing smoking during pregnancy, although there have been some notable efforts in that direction mostly around how changes in smoking status during treatment impact use of neonatal intensive care services (e.g., Ayadi et al., 2006) .

In a fiscal climate in which U.S. federal and state funding for public health has been generally declining since the 2008 economic crisis (Trust for America's Health, 2018) or directed to in 2020, the paucity of economic information will likely stall efforts to increase the scope and intensity of smoking-cessation services for pregnant women. That is not a minor problem as there is broad consensus regarding the need for more effective interventions for smoking cessation during pregnancy (Higgins & Solomon, 2016; Scherman et al., 2018; USDHHS, 2018) . A programmatic series of metaanalyses from Cochrane Reviews on interventions for smoking cessation among pregnant women, which now include more than 77 RCTS and 25,000 women, provide compelling evidence that these interventions increase cessation rates (Chamberlain et al., 2013; Chamberlain et al., 2017; Lumley et al., 2009) . However, cessation rates across the different interventions examined in these comprehensive meta-analyses are quite modest. They are generally only about 6 percentage points better than control levels. That effect size is too modest to be satisfactory when dealing with a problem that causes catastrophic outcomes such as SUID and a wide range of other serious adverse pregnancy (e.g., ectopic pregnancy, placental abruption, premature rupture of membranes) and birth outcomes (fetal growth restriction, oral-facial deformities) and greater later-in-life disease risk (e.g., metabolic disorders) (Franco et al., 1999; USDHHS, 2004; 2014; Weese-Mayer et al., 2008) .

There are many reasons why smoking during pregnancy is difficult to treat (e.g., maternal socioeconomic disadvantage, stigma, concerns regarding potential adverse effects of smokingcessation medications), but to obtain larger effect sizes among pregnant women, more intensive and hence more expensive interventions are likely necessary (Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff, 2008; Higgins et al., 2016) . For example, as early as 2009 a meta-analysis noted that financial incentives usually offered in combination with routine care were significantly more successful in achieving late-pregnancy cessation than other approaches (Lumley et al., 2009) . Instead of the overall average 6% increase, financial incentives were shown to increase late-pregnancy cessation rates by an average of approximately 23% or an aOR of late-pregnancy cessation of 3.79 (95% CI, 2.74-5.25) compared to control interventions (Cahill et al., 2015; Higgins & Solomon, 2016; Lumley et al., 2009 ).

Nevertheless, financial incentives are not used in routine care for smoking during pregnancy, with cost concerns being a common explanation offered for ignoring that evidence (Higgins et al., 2019) .

Hence, the need for and importance of epidemiological studies like Anderson et al., 2019 that are sufficiently powered statistically to delineate the health impacts of decreasing smoking during pregnancy on health outcomes. In addition to supporting the rationale for developing more intensive and likely more costly interventions, this information can also support efforts to increase use of existing evidence-based interventions.

As a step towards examining the economic value of preventing SUID through smoking cessation or reductions in smoking intensity during pregnancy, we used the SUID risk estimates from Anderson et al., 2019 to estimate the total monetary value of economic benefits from preventing SUID deaths attributed to smoking during pregnancy and economic costs of SUID deaths. By putting a monetary value on smoking-attributable SUID deaths, we hope to draw attention to the potential J o u r n a l P r e -p r o o f Journal Pre-proof economic benefit of greater efforts to reduce smoking during pregnancy and the economic cost that results from not doing so. Anderson et al.'s five-year (2007-11) data set contained an average of approximately 4.14 million births per year. Of these, an estimated 368,000 women who reported smoking during pregnancy using the 8.9% smoking prevalence in the final year of their 5-year data set as a conservative estimate. Among these pregnant smokers, approximately 77,322 (21%) reported quitting by the third trimester, 88,368 (24%) reported reducing smoking intensity by the third trimester, while the remaining 202,511 (55%) reported continued smoking with no reduction in intensity. Compared to women who continued smoking at same intensity, SUID risk was reduced by 23% (aOR = 0.77; 95% CI, 0.67-0.87) among women who quit and 12% (aOR = 0.88; 95% CI, 0.79-0.98) among those who reduced smoking intensity. These differences in SUID rates by smoking status and associated CIs provided the resulting estimates and CIs in deaths averted discussed below and in the Table. The economic value of life has been conceptualized as including both the value of an individual's contribution to economic production over their remaining lifetime plus the additional value people place on the enjoyment of life (for reviews see Robinson et al., 2017; Shillcutt et al., 2009 ). Although the literature on valuing life is extensive, few prior methodological studies offer specific guidance on valuing infant lives. Here we apply the 2020 value of a statistical life of $10.1 million using guidelines from the U.S. Department of Health and Human Services for making health policy (USDHHS, 2016) . Using that 2020 value, we estimate (see Table) that the values gained from the reduced SUIDS risk per pregnant smoker who quits or reduces by the start of the third trimester compared to continued smoking are $4700 (95% CI $2700-$6800) and $2500 ($400-$4300), respectively. We derived these values by starting with the rate of SUID in woman who continued smoking and translating the relative reductions from reducing or abstaining into the absolute reduction in SUID risk per 1,000 pregnancies. We then multiplied these absolute reductions in deaths averted J o u r n a l P r e -p r o o f Journal Pre-proof times the aforementioned value of a statistical life. Just these benefits alone would exceed the combined costs of smoking-cessation counseling, a 10-week course of nicotine replacement therapy, and financial incentives (e.g., see Boyd et al. 2016 ).

Using these figures, we then estimated the monetary benefit the United States likely realizes each year from current smoking reductions and quits by third trimester compared to all pregnant smokers continuing to smoke throughout pregnancy without reducing or quitting, and found this was around $0.58 (95% CI $0.35-$0.82) billion. We also estimated the value to be gained each year of further reducing the prevalence of smoking during the third trimester of pregnancy from current prevalence levels to 0 prevalence. We estimate that if all pregnant smokers quit and remained abstinent in the third trimester, the additional aggregate economic benefits would be $1.16 (95% CI, $0.71-$1.60) billion per year. If all pregnant smokers who were continuing at their initial rate simply reduced their smoking, the aggregate economic benefits would be $0.50 (95%CI 0.08-0.87) billion per year. We calculated each of these national amounts (and CIs) by summing of products of the actual values per woman (with associated CIs, before rounding) times the national numbers of women in each smoking sub-category (e.g., $4737 x 202,511 + [$4737 -$2475] x 88,368 = $1.16 billion). (Little et al., 2004; USDHHS, 2018, Chapter 4 ). There is little question that smoking during pregnancy remains a substantial U.S. public health problem. There is broad agreement on the need for more effective interventions to reduce this problem (Chamberlain et al., 2013; Chamberlain et al., 2017; Higgins & Solomon, 2016; Lumley et al., 2009) 

SIDS and other sleep-related infant deaths: Updated 2016 recommendations for a safe infant sleeping environment

Passive smoking and sudden infant death syndrome: review of the epidemiological evidence

Maternal smoking before and during pregnancy and the risk of sudden unexpected death

Costs of a smoking cessation counseling intervention for pregnant women: comparison of three settings

Are financial incentives cost-effective Centers for Disease Control and Prevention. Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAMMEC) -Smoking-Attributable Mortality (SAM)

Psychosocial interventions for supporting women to stop smoking in pregnancy

Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence

Concurrent prenatal drinking and smoking increases risk for SIDS: Safe Passage Study report

Misclassification of maternal smoking status and its effects on an epidemiologic study of pregnancy outcomes

Evaluation of a federally funded mass media campaign and smoking cessation in pregnant women: a populations based study in three states

Prenatal exposure to cigarette smoking is associated with a decrease in arousal in infants

Effects of voucher-based incentives on abstinence from cigarette smoking and fetal growth among pregnant women

Voucher-based Contingency Management is efficacious but underutilized in treating addictions

Some developments on financial incentives for smoking cessation among pregnant and newly postpartum women

Effects of maternal tobacco smoking, sleeping position, and sleep state on arousal in healthy term infants

Tobacco smoking and oral clefts: a meta-analysis

Interventions for promoting smoking cessation during pregnancy

SIDS: past, present, and future

Smoking and the sudden infant death syndrome

The combination of bed sharing and maternal smoking leads to a greatly increased risk of sudden unexpected in infancy: the New Zealand SUDI Nationwide Case Control Study

Smoking prevalence among U.S. national samples of pregnant women

Prenatal substance use and perceptions of parent and partner use using the 4Ps plus screener

Arousal and ventilator responses to hypoxia in sleeping infants: effects of maternal smoking

Outpatient-or community-based interventions to prevent SIDS and sleeprelated deaths

Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy and Planning

Smoking cessation in pregnancy: a continuing challenge in the United States

Cost effectiveness in low-and middleincome countries

Sudden infant and early childhood death: The past, present and the future

Financial incentives for smoking cessation in pregnancy: randomized controlled trial

This project was supported in part by a Tobacco Centers of Regulatory Science (TCORS) award